HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Evaluation of the anti-tumour activity of Coriolus versicolor polysaccharopeptide (I'm-Yunity) alone or in combination with doxorubicin for canine splenic hemangiosarcoma.

Abstract
Canine splenic hemangiosarcoma (HSA) is an aggressive tumour of vascular endothelium that carries a grave prognosis following standard of care treatment with surgery and doxorubicin. A previous pilot study revealed potential anti-tumour activity of I'm-Yunity polysaccharopeptide (PSP) for canine HSA. The aim of this prospective study was to assess patient outcome when treated with PSP alone or in combination with doxorubicin post-splenectomy compared to patients treated with surgery and doxorubicin that received a placebo in place of PSP. Dogs undergoing splenectomy for splenic HSA were eligible. Following splenectomy, owners were offered treatment with PSP alone or adjuvant doxorubicin chemotherapy (unblinded). Patients with owners that selected to proceed with doxorubicin chemotherapy were blindly randomized to receive placebo or PSP. Dogs were evaluated weekly for 15 weeks, then scheduled for monthly visits until death. One hundred and one dogs were included in the final analysis: 51 PSP alone, 25 doxorubicin/placebo, and 25 combination PSP/doxorubicin. On multivariate analysis, dogs treated with single agent PSP, female dogs, decreased haematocrit at diagnosis, and stage III disease were negatively significantly associated with outcome; however, an interaction between treatment group and sex was documented. Gender-specific outcomes revealed no significant difference in survival between treatment groups for male dogs, but female dogs treated with PSP alone had significantly reduced survival compared to females receiving doxorubicin/placebo (HR 0.21; p = .004). Anaemia (HR 5.28; p < .001) and stage III disease (HR 2.9; p = .014) remained negatively associated with survival when controlling for sex and treatment group. The addition of PSP to doxorubicin post-splenectomy did not improve survival in dogs with splenic HSA.
AuthorsAllison Gedney, Pascale Salah, Jennifer A Mahoney, Erika Krick, Reenie Martins, Heather Scavello, Jennifer A Lenz, Matthew J Atherton
JournalVeterinary and comparative oncology (Vet Comp Oncol) Vol. 20 Issue 3 Pg. 688-696 (Sep 2022) ISSN: 1476-5829 [Electronic] England
PMID35442554 (Publication Type: Journal Article, Randomized Controlled Trial, Veterinary)
Copyright© 2022 John Wiley & Sons Ltd.
Chemical References
  • Drugs, Chinese Herbal
  • I'm-Yunity
  • Proteoglycans
  • polysaccharide peptide
  • Doxorubicin
Topics
  • Animals
  • Dog Diseases (drug therapy)
  • Dogs
  • Doxorubicin (therapeutic use)
  • Drugs, Chinese Herbal
  • Female
  • Hemangiosarcoma (drug therapy, veterinary)
  • Male
  • Pilot Projects
  • Polyporaceae
  • Prospective Studies
  • Proteoglycans
  • Splenic Neoplasms (drug therapy, veterinary)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: